RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
RxSight, Inc. (RXST) Q2 2026 Earnings Call Transcript
Seeking Alpha8/6/2026Neutral
RXST
Rxsight IncNASDAQHEALTHCAREMEDICAL DEVICES
Key Statistics
Market Cap
$269.52M
P/E Ratio
—
EPS
$-1.07
Beta
1.13
52W High
$13.22
52W Low
$4.48
50-Day MA
$5.50
200-Day MA
$7.75
Dividend Yield
—
Profit Margin
-36.80%
Forward P/E
116.28
PEG Ratio
—
About Rxsight Inc
Rxsight Inc. is a cutting-edge healthcare technology company dedicated to transforming vision correction through advanced diagnostic and surgical solutions in refractive eye surgery. By integrating proprietary software with precision laser systems, Rxsight aims to significantly improve patient outcomes and enhance the quality of life for those seeking vision correction. The company boasts a robust intellectual property portfolio and strategic collaborations that position it favorably within the growing ophthalmic market. Committed to innovation and operational excellence, Rxsight is poised to drive substantial advancements in eye care, reflecting its potential for sustained growth and impact in the sector.
Fundamentals
| Revenue (TTM) | $127.58M |
| Gross Profit (TTM) | $98.88M |
| EBITDA | $-51.58M |
| Operating Margin | -40.80% |
| Return on Equity | -17.30% |
| Return on Assets | -10.40% |
| Revenue/Share (TTM) | $3.09 |
| Book Value | $6.46 |
| Price-to-Book | 1.09 |
| Price-to-Sales (TTM) | 2.11 |
| EV/Revenue | 0.693 |
| EV/EBITDA | -7.70 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.30% |
| Shares Outstanding | $41.59M |
| Float | $36.26M |
| % Insiders | 6.42% |
| % Institutions | 100.45% |
Historical Volatility
HV 10-Day
60.86%
HV 20-Day
65.99%
HV 30-Day
64.63%
HV 60-Day
65.79%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($7.79 target)
1
Strong Buy7
Hold2
Strong SellLatest News
RxSight Q2 Earnings Call Highlights
RxSight NASDAQ: RXST reported second-quarter revenue of $33.7 million, including $6.5 million recognized under its strategic collaboration with Alcon, while management withdrew its full-year 2026 financial guidance as new Chief Executive Officer Aziz Mottiwala conducts a broader assessment of the business.
MarketBeat8/6/2026Positive
RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook
ALISO VIEJO, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today reported financial results for the quarter ended June 30, 2026, and provided an update on its 2026 financial outlook.
GlobeNewsWire8/5/2026Neutral
Earnings Preview: RxSight, Inc. (RXST) Q2 Earnings Expected to Decline
RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research7/29/2026Negative
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
ALISO VIEJO, Calif., July 26, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced that on July 24, 2026, RxSight granted inducement stock options to purchase a total of 571,286 shares of RxSight's common stock and inducement restricted stock units (RSUs) covering a total of 2,312,138 shares of RxSight's common stock to Aziz Mottiwala, RxSight's new President and Chief Executive Officer in connection with his commencement of employment with RxSight.
GlobeNewsWire7/26/2026Neutral
RxSight (RXST) Surges 6.1%: Is This an Indication of Further Gains?
RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research7/17/2026Positive
RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer
ALISO VIEJO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced a planned leadership transition effective July 20, 2026, with Aziz Mottiwala appointed President and Chief Executive Officer, succeeding Ron Kurtz, M.D., who will continue to serve as Chief Medical Officer.
GlobeNewsWire7/15/2026Neutral
Alcon & RxSight Collaborate to Develop Adjustable PCIOL Technology
ALC is developing adjustable presbyopia-correcting lenses that pair advanced optics with post-surgery light adjustment.
Zacks Investment Research7/13/2026Positive
RxSight: After Dropping To The Bottom, It's Time To Pick It Up
RxSight, Inc. exhibits quantitative similarities to other small caps that I have rated here on Seeking Alpha that strongly outperformed the market. RXST is an 'NCAV' opportunity, a company that sells for less than its current asset value even though management is putting the company back on the growth track. My thesis is grounded in historical patterns where cash-rich, loss-making small caps often resolve operational issues before exhausting reserves.
Seeking Alpha7/10/2026Positive
Law Offices of Howard G. Smith Announces Investigation of RxSight, Inc. (RXST) on Behalf of Investors
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces it is investigating potential claims against the board of directors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) concerning whether the board breached its fiduciary duties to shareholders.IF YOU ARE A RXSIGHT, INC. (RXST) SHAREHOLDER, CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE.What Is The Investigation About?On July 8, 2025, after the market closed, RxSight reported preliminary second quarter.
Business Wire7/8/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RXST and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026